跳至主要内容
临床试验/NCT01819194
NCT01819194已完成不适用

Contact Lens Comfort Relative to Meibomian Gland Status

Johnson & Johnson Vision Care, Inc.1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2013年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
64
试验地点
1
主要终点
Comfort as Measured by the Contact Lens Users Experience Questionnaire (CLUE)

研究概览

简要总结

This trial aims to establish a correlation between patient reported comfort while using soft contact lenses and meibomian gland dysfunction (MGD).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 39 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • The subject must be able to read, understand, and sign the statement of informed consent and receive a fully executed copy of the form.
  • The subject be able and willing to adhere to the instructions set forth in this clinical protocol.
  • The subject must be 18 and less than 39 years of age.
  • The subject must be an adapted soft contact lens wearer in both eyes (Defined as having been a full times lens wearer for at least 3 months).
  • Subjects must be current full time daily wearers of Acuvue Oasys lenses (defined as, at least 6 hours per day, 5 days per week).
  • The subject's spherical equivalent distance refraction must be in the range of 0.00 to -6.00D in each eye.
  • The subject must present at visit 1 with a current copy of their spectacle prescription.
  • The subject must have the best corrected visual acuity of 0.18 or better in each eye as assessed by LogMAR chart.
  • The subject must have normal eyes (i.e., no ocular medication, or infections of any type)

排除标准

  • Wear Acuvue Oasys with Hydraclear Plus on an extended wear basis.
  • Wear Acuvue Oasys with Hydraclear Plus for astigmatism.
  • History of epithelial herpes simplex keratitis (dendritic keratitis); vaccinia, active or recent varicella, viral disease of the cornea and/or conjunctiva; chronic bacterial disease of the cornea and/or conjunctiva; mycobacterial infection of the eye; and/or fungal disease of the eye.
  • Use of concomitant ocular medications during the study period. Topical artificial tears or contact lens lubricants are allowed, but no instillation on the day of examinations.
  • Any systemic disease, autoimmune disease, or use of medications, which may interfere with contact lens wear.
  • Subjects using medications influencing tear production such as steroids, immunosuppressive agents and/or anti-cholinergics (e.g. cold and allergy medications, tricyclic antidepressants) for treatment of autoimmune connective tissue disease may not be enrolled in this study if they have not been on a stable dosing regimen for 30 days prior to the Eligibility Visit. Subjects may use birth control medications since there is inconclusive evidence relative to the influence on tear film.
  • Any infectious disease (e.g. Hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV, by self report).
  • Subjects reporting discomfort at screening visit related to fit or care system abnormalities (both determined by the investigator), ocular conditions such as conjunctival infections, iritis.
  • Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
  • Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
  • Entropion, ectropion, extrusion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosion,aphakia, or moderate or above corneal distortion by keratometry.
  • Any previous, or planned, ocular or intraocular surgery (radial keratotomy, LASIK, ETC.)
  • Any grade 3 or greater slit lamp findings (e.g. edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g. past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear.
  • Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
  • Monovision or multi-focal contact lens correction
  • Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment
  • History of binocular vision abnormality or strabismus
  • History of serious mental illness
  • History of seizures

结局指标

主要结局

Comfort as Measured by the Contact Lens Users Experience Questionnaire (CLUE)

时间窗: Post 3 days of wear

CLUE is survey that is used to assess subjective comfort of the test article. The higher the score the better on a range of 0 to 120.

Meibbomian Gland Dysfunction (MGD)as Measured by MGD Scale

时间窗: Post 3 days of wear

Meibomian Gland Dysfunction (MGD) as measured using the MGD 0 - 11 scale translated into grades 0 to 3 where 0 refers to absence of markers.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验